Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
beta-catenin degrader
- Development stage
- Preclinical
- Lead developer
- Parabilis Medicines
- Modality
- Peptides, PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
01
Overview
This beta-catenin degrader is a preclinical-stage therapeutic being developed by Parabilis Medicines for the treatment of solid tumors driven by the Wnt/beta-catenin signaling pathway. The drug candidate utilizes the company's proprietary Helicon platform, which consists of stabilized alpha-helical peptides designed to bind targets that are traditionally considered undruggable. By binding to beta-catenin with high affinity, the Helicon-enabled degrader facilitates the recruitment of the cellular ubiquitin-proteasome machinery, leading to the targeted degradation of the protein. This mechanism aims to inhibit the aberrant gene expression and oncogenic signaling associated with beta-catenin accumulation, which is a hallmark of various cancers, most notably colorectal cancer.
- Other names
- beta-catenin degrader (Parabilis Medicines)Helicon-enabled beta-catenin degraderCTNNB1 degraderCTNNB-1 degraderCTNNB 1 degrader
02
Targets
CTNNB1 (Beta-catenin)
Beyond the preview
Go deeper on beta-catenin degrader.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on beta-catenin degrader.